File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1136/ard.59.6.462
- Scopus: eid_2-s2.0-0034121183
- PMID: 10834864
- WOS: WOS:000087533300014
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: Is there a role for antiphospholipid antibodies?
Title | Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: Is there a role for antiphospholipid antibodies? |
---|---|
Authors | |
Issue Date | 2000 |
Publisher | B M J Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/ |
Citation | Annals Of The Rheumatic Diseases, 2000, v. 59 n. 6, p. 462-467 How to Cite? |
Abstract | Background - Avascular necrosis of bone (AVN) is a well known complication in patients with systemic lupus erythematosus (SLE). Objective - To investigate the role of antiphospholipid antibody status (IgM and IgG anticardiolipin antibodies and lupus anticoagulant) with adjustment for corticosteroid use as risk factors for the development of AVN. Methods - A cohort of 265 patients receiving long term follow up in our SLE clinic from 1978 to 1998 was analysed. Patients with AVN complications were detected and then matched for age, sex, ethnicity, duration of disease, and organ disease with two other patients with SEE. A further 31 patients were chosen at random for the analysis. Results - Eleven patients had AVN, giving a point prevalence of 4%. There were no significant differences demonstrable in the presence of individual antiphospholipid antibodies (aPL) or their combination between the group with AVN or the two control groups. Conclusion - Incorporating an adjustment for corticosteroid use we were unable to show a link between the presence of aPL and the development of AVN in patients with SLE. |
Persistent Identifier | http://hdl.handle.net/10722/162429 |
ISSN | 2023 Impact Factor: 20.3 2023 SCImago Journal Rankings: 6.138 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mok, MY | en_US |
dc.contributor.author | Farewell, VT | en_US |
dc.contributor.author | Isenberg, DA | en_US |
dc.date.accessioned | 2012-09-05T05:19:50Z | - |
dc.date.available | 2012-09-05T05:19:50Z | - |
dc.date.issued | 2000 | en_US |
dc.identifier.citation | Annals Of The Rheumatic Diseases, 2000, v. 59 n. 6, p. 462-467 | en_US |
dc.identifier.issn | 0003-4967 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/162429 | - |
dc.description.abstract | Background - Avascular necrosis of bone (AVN) is a well known complication in patients with systemic lupus erythematosus (SLE). Objective - To investigate the role of antiphospholipid antibody status (IgM and IgG anticardiolipin antibodies and lupus anticoagulant) with adjustment for corticosteroid use as risk factors for the development of AVN. Methods - A cohort of 265 patients receiving long term follow up in our SLE clinic from 1978 to 1998 was analysed. Patients with AVN complications were detected and then matched for age, sex, ethnicity, duration of disease, and organ disease with two other patients with SEE. A further 31 patients were chosen at random for the analysis. Results - Eleven patients had AVN, giving a point prevalence of 4%. There were no significant differences demonstrable in the presence of individual antiphospholipid antibodies (aPL) or their combination between the group with AVN or the two control groups. Conclusion - Incorporating an adjustment for corticosteroid use we were unable to show a link between the presence of aPL and the development of AVN in patients with SLE. | en_US |
dc.language | eng | en_US |
dc.publisher | B M J Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/ | en_US |
dc.relation.ispartof | Annals of the Rheumatic Diseases | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Antibodies, Anticardiolipin - Blood | en_US |
dc.subject.mesh | Antibodies, Antiphospholipid - Blood | en_US |
dc.subject.mesh | Biological Markers - Blood | en_US |
dc.subject.mesh | Case-Control Studies | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Follow-Up Studies | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunoglobulin G - Analysis | en_US |
dc.subject.mesh | Immunoglobulin M - Analysis | en_US |
dc.subject.mesh | Lupus Coagulation Inhibitor - Blood | en_US |
dc.subject.mesh | Lupus Erythematosus, Systemic - Complications - Immunology | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Osteonecrosis - Etiology - Immunology | en_US |
dc.subject.mesh | Risk Factors | en_US |
dc.title | Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: Is there a role for antiphospholipid antibodies? | en_US |
dc.type | Article | en_US |
dc.identifier.email | Mok, MY:temy@hkucc.hku.hk | en_US |
dc.identifier.authority | Mok, MY=rp00490 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1136/ard.59.6.462 | en_US |
dc.identifier.pmid | 10834864 | en_US |
dc.identifier.scopus | eid_2-s2.0-0034121183 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0034121183&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 59 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.spage | 462 | en_US |
dc.identifier.epage | 467 | en_US |
dc.identifier.isi | WOS:000087533300014 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Mok, MY=7006024184 | en_US |
dc.identifier.scopusauthorid | Farewell, VT=7005718187 | en_US |
dc.identifier.scopusauthorid | Isenberg, DA=36051280800 | en_US |
dc.identifier.issnl | 0003-4967 | - |